The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 05, 2016
Filed:
Feb. 24, 2014
Applicant:
Xeris Pharmaceuticals, Inc., Austin, TX (US);
Inventors:
Steven Prestrelski, San Diego, CA (US);
John Kinzell, San Rafael, CA (US);
Assignee:
Xeris Pharmaceuticals, Inc., Austin, TX (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/29 (2006.01); A61K 38/22 (2006.01); A61K 38/26 (2006.01); A61K 38/28 (2006.01); A61K 47/26 (2006.01); A61K 9/00 (2006.01); A61K 9/19 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2006.01); A61K 47/12 (2006.01); A61K 47/14 (2006.01); A61K 47/18 (2006.01); A61K 47/20 (2006.01); A61K 47/22 (2006.01); A61K 38/09 (2006.01); A61K 38/16 (2006.01); A61K 38/17 (2006.01); A61K 38/18 (2006.01); A61K 38/25 (2006.01); A61K 38/30 (2006.01); A61K 38/48 (2006.01);
U.S. Cl.
CPC ...
A61K 47/26 (2013.01); A61K 9/0019 (2013.01); A61K 9/19 (2013.01); A61K 38/09 (2013.01); A61K 38/16 (2013.01); A61K 38/17 (2013.01); A61K 38/1709 (2013.01); A61K 38/1816 (2013.01); A61K 38/22 (2013.01); A61K 38/2207 (2013.01); A61K 38/25 (2013.01); A61K 38/26 (2013.01); A61K 38/28 (2013.01); A61K 38/29 (2013.01); A61K 38/30 (2013.01); A61K 38/4893 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); A61K 47/183 (2013.01); A61K 47/20 (2013.01); A61K 47/22 (2013.01);
Abstract
Stable formulations for parenteral injection of peptide drugs and methods of using such stable formulations are provided. In particular, the present invention provides stable formulations for parenteral injection of glucagon and methods of using such glucagon formulations to treat hypoglycemia, especially severe hypoglycemia in emergency situations.